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Abstract
A high-throughput, cell-based screen was used to identify chemotypes as inhibitors for human
respiratory syncytial virus (hRSV). Optimization of a sulfonylpyrrolidine scaffold resulted in
compound 5o that inhibited a virus-induced cytopathic effect in the entry stage of infection (EC50
= 2.3 ± 0.8 µM) with marginal cytotoxicity (CC50 = 30.9 ± 1.1 µM) and reduced viral titer by 100-
fold. Compared to ribavirin, sulfonylpyrrolidine 5o demonstrated an improved in vitro potency
and selectivity index.
INTRODUCTION
Human respiratory syncytial virus (hRSV) is the most common cause of bronchiolitis and
pneumonia among infants and children under one year of age.1 In the United States there are
approximately 125,000 yearly hRSV-related hospitalizations, and of those, 500 young
children could die due to the infection or its complications each year.2 The virus is highly
contagious and affects those with compromised cardiac, pulmonary (COPD), and immune
systems.3 As such, the elderly are also a highly susceptible population to hRSV. Treatment
options are limited. Due to infant mortality associated with attempted vaccination, vaccine
development is proceeding cautiously.4,5 Synagis® (Palivizumab), a humanized monoclonal
antibody, is a prophylactic, injectable therapeutic used only with high risk pediatric
patients.6 Ribavirin, a nucleoside antimetabolite, is approved for acute infection7,8 and
infected, immunocompromised patients,9 but has a long half-life and accumulates in
erythrocytes, thus requiring regeneration of the affected red blood cells to eliminate the
*Corresponding Author Phone (502) 852-1546. weseve01@louisville.edu.
£Current address: Department of Biochemistry & Molecular Genetics, University of Alabama, Birmingham, AL. USA
¥Current Address: Department of Molecular & Cellular Biology, Baylor College of Medicine, Houston, TX, USA
Supporting Information. Assay details and experimental characterization for select compounds. This material is available free of
charge via the internet at http://pubs.acs.org.
NIH Public Access
Author Manuscript
J Med Chem. Author manuscript; available in PMC 2013 October 25.
Published in final edited form as:










drug. These issues, coupled with embryocidal and teratogenic effects constitute severe
toxicological liabilities that limit the use of ribavirin, especially in infants,7 around
administering pregnant medical personnel, and in treated partners of pregnant women
(Figure 1).
To address the absence of clinically relevant and safe hRSV therapies, many investigators
have pursued a target-based drug design approach. Ribavirin 5′-monophosphate resembles
GMP and can decrease cellular GTP pools due to the inhibition of the enzyme inosine
monophosphate dehydrogenase (IMPDH).10,11 Nevertheless, this decrease does not
completely account for the observed antiviral activity as inhibitory effects have been noted
on RNA capping12 and direct inhibition of viral polymerase activity for influenza viruses.13
Literature disclosed IMPDH inhibitors have reported in vitro therapeutic indices that are not
competitive with ribavirin.14 Several other inhibitors that target the fusion protein,15–20
ribonucleoprotein (RNP) complex,21 guanylylation events,22 and N-protein23 have been
discovered. Of these, some demonstrate potency and limited toxicity in animal models.24–26
However, due to formulation for oral bioavailability,19 strategic reasons,27 and observed
loss of activity in vivo,28 many have not progressed to the clinic to combat hRSV disease.
In an effort to identify lead compounds acting through new mechanisms, we developed,
optimized and validated a high-throughput cell-based screen that measures the respiratory
syncytial virus-induced cytopathic effect (CPE) in HEp-2 cells (unpublished results). CPE
was measured using the Cell Titer-Glo™ viability assay in which the luminescent signal
generated is directly proportional to the amount of cellular ATP present which is also
proportional to the number of metabolically active cells. A total of 313,816 compounds from
the Molecular Libraries Small Molecule Repository (MLSMR) were screened in single dose
against hRSV (strain Long) at a concentration of 10 µM. Hits (2,465 compounds) were
evaluated for their antiviral activity and cell toxicity in dose response experiments, and 409
compounds produced a protective effect of at least 50% CPE inhibition. Based on potency,
selectivity and chemical tractability, 51 hits were selected for verification in an in vitro titer
reduction assay to assess their effect on the production of infectious progeny virus. Many
chemotypes of interest emerged, including several compounds containing a
sulfonylpyrrolidine moiety. Hit compound 2 displayed a CPE EC50 of 5.0 µM, a CC50
(HEp-2 cellular cytotoxicity) of 31.5 µM, and a selectivity index (CC50/EC50) of 6.3 (Figure
2). Profile improvements were explored by modulating various structural elements (shaded
regions, Figure 2).
CHEMISTRY
Analogs were prepared by treating substituted sulfonyl chlorides 3 with proline or another
suitable amino acid to generate sulfonamide carboxylates 4. Coupling of the acids to various
amines via traditional methods afforded the desired products 5 (Scheme 1).
RESULTS AND DISCUSSION
Attention was first placed on the proline unit between the aryl sulfone and aniline groups.
The hit compound 2 was tested as a racemic mixture; therefore, each enantiomer was
individually prepared from L- or D-proline to determine the more pharmacologically active
constituent. The S-enantiomer, derived from L-proline, was found to be the more active
component of the racemic mixture, delivering a selectivity index of 11.8 when cytotoxicity
was accounted for (entry 4, Table 1). This compound showed a 1 log reduction in virus titer
in a plaque reduction assay. Acyclic variants of the linker region, including those that
probed the methylation of the amide nitrogen, were found to have EC50 values > 50.0 µM.
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Several variants of the quinoline moiety were pursued but offered no benefit in potency.
Replacing the nitrogen atom with –CH- afforded an inactive analog (EC50 > 50.0 µM), as
did migrating the nitrogen to alternate positions of the quinoline substructure. The
replacement of the quinoline with a 4-linked-benzooxadiazole, a phenyl ring or a simple
methyl group was also not advantageous. Substitution of the sulfonyl group (SO2) for a
carbonyl functionality or its replacement with –CH2- resulted in complete loss of potency
(EC50 > 50.0 µM, see supporting information, Tables S1 and S2, respectively). Focus was
then shifted to the modification of the 2,4-dimethylanilide. Following the results noted
above, all analogs in this study were prepared as the S-enantiomer (Table 2). Simplifying the
2,4-dimethylphenyl substitution pattern down to monomethyl substituted phenyl derivatives
revealed that the observed potency was not due to the presence of one group alone (entries
3–5). Increased steric bulk at C2 marginally improved potency vs. monomethyl substitution
at the same position (cf. entries 8 to 7). Mimicking the 2,4-substitution pattern with chlorine
atoms in place of methyl groups resulted in complete loss of potency (5n, entry 11). As the
2-alkyl substituent appeared to be necessary in combination with other substituents to
preserve potency, this dynamic was explored further to reveal that the 2,5-dimethylphenyl
moiety of analog 5o was slightly more beneficial in terms of potency and maintained the
cytotoxicity threshold (entry 12, EC50 = 2.3 µM, CC50 = 30.9 µM). For select compounds
assessed for aqueous solubility, no effect was observed on CPE potency. Solubility and
stability were determined for 5o, revealing an acceptable solubility measurement of 92.7 µg/
mL in PBS buffer and stability of 95.4% (unchanged parent remaining) after 48 h in 50%
PBS/50% acetonitrile.29
To probe the mechanism of action of the sulfonylpyrrolidines, the window of inhibitory
activity in the cell-based assay was refined. Potency of compounds over time following
infection was examined to ascertain early (entry) or late (replication) antiviral activity in the
virus life cycle.30
In the time of addition study, HEp-2 cells were infected with hRSV strain Long at an MOI
of 3.0 at time point 0 and incubated for 6 days and test compounds, 5b, 5t, 5o, or ribavirin
were added to plates at −1, 0, 1, 2, 3, 5, 7, 21 and 24 h post infection (p.i.). CPE was
assessed using Cell-Titer Glo as an endpoint reagent. Controls without test compound
included HEp-2 cells with no hRSV exposure (cell control) and hRSV-infected cells (virus
control). To evaluate cellular toxicity attributed to test compound alone, uninfected HEp-2
cells were treated with 5b, 5t, 5o, or ribavirin at 25 µM concentration at time point 0, and
cell viability was assessed after 144 hours.
There was less than 1% cell viability for the hRSV-infected cells without addition of any test
compound or ribavirin. Uninfected cells treated with ribavirin, 5t or 5o displayed 90%, 88%
and 95% cell viability, respectively, indicating low cellular toxicity inherent to these
compounds. However, uninfected cells treated with 5b exhibited only 46% cellular viability,
suggesting moderate toxicity due to the test compound alone.31 Ribavirin treatment
protected cells from hRSV induced CPE for up to 7 h p.i., indicating that it targets the period
of infection during which viral replication is in progress. Compound 5o protected cells from
hRSV induced CPE (> 50%) from 1 – 3 h p.i., and at 24 h p.i. cell viability was only 26%.
(Figure 3).
Two analogs of similar profile to 5o, 5b and 5t, demonstrated a decrease in efficacy when
added at each time point from 0–5 hours p.i. This profile could be due to the inhibition of
one or more early virus life cycle steps (entry, post-entry, or early-stage infection processes),
a hypothesis that is supported by an inability of these compounds to affect processes later in
the viral replication cycle. This data lead us to conclude that 5o was inhibiting early
infection events, characterized by viral attachment, uptake, fusion or initial transcription.
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The sulfonylpyrrolidine scaffold analogues were evaluated for their ability to reduce the
amount of infectious virus produced in cell culture. These measurements of compound-
mediated viral titer reduction were used to complement the cytoprotection assay results. A
standard plaque-reduction assay was used as a secondary assay to determine the ability of
this class of compounds to reduce the amount of infectious virus produced in HEp-2 cells.32
Cells were infected with hRSV in the presence of 25 µM test compound (5b, 5o, or 5t).
Compounds 5b and 5t each showed 1 log reduction in virus titer, or 10-fold, as compared to
ribavirin which reduced viral titer by 2.5 log units, or ~300-fold. Analog 5o showed a 100-
fold, or 2 log, reduction. Improvements in cell protection against hRSV did not translate to
significant improvement in the plaque assay as was seen with ribavirin. Consequently, the
titer reduction assay was not used to drive SAR efforts.
CONCLUSION
In summary, the HTS and chemistry optimization efforts produced a series of
enantiomerically pure, sulfonylpyrrolidine-based compounds that are effective in vitro
inhibitors of hRSV in the low micromolar range. Many of these compounds were shown to
reduce the in vitro viral titer by 100-fold. The therapeutic index for the series was
maximized at 13.4-fold and is an issue for further refinement preceding in vivo assessment.
EXPERIMENTAL SECTION
Chemistry
All final compounds were confirmed to be of >95% purity based on HPLC analysis. 1H
and 13C NMR spectra were recorded on a Bruker AM 400 spectrometer (operating at 400
and 101 MHz respectively) or a Bruker AVIII spectrometer (operating at 500 and 126 MHz
respectively) in CDCl3 with 0.03% TMS as an internal standard or DMSO-d6. The chemical
shifts (δ) reported are given in parts per million (ppm) and the coupling constants (J) are in
Hertz (Hz). The spin multiplicities are reported as s = singlet, bs = broad singlet, d =
doublet, t = triplet, q = quartet, dd = doublet of doublet and m = multiplet. The LCMS
analysis was performed on an Agilent 1200 RRL chromatograph with photodiode array UV
detection and an Agilent 6224 TOF mass spectrometer. The chromatographic method
utilized the following parameters: a Waters Acquity BEH C-18 2.1 × 50mm, 1.7 µm column;
UV detection wavelength = 214 nm; flow rate = 0.4ml/min; gradient = 5 – 100% acetonitrile
over 3 minutes with a hold of 0.8 minutes at 100% acetonitrile; the aqueous mobile phase
contained 0.15% ammonium hydroxide (v/v). The mass spectrometer utilized the following
parameters: an Agilent multimode source which simultaneously acquires ESI+/APCI+; a
reference mass solution consisting of purine and hexakis(1H, 1H, 3H-tetrafluoropropoxy)
phosphazine; and a make-up solvent of 90:10:0.1 MeOH:Water:Formic Acid which was
introduced to the LC flow prior to the source to assist ionization. Melting points were
determined on a Stanford Research Systems OptiMelt apparatus.
Synthesis of (S)-N-(2,5-Dimethylphenyl)-1-(quinolin-8-ylsulfonyl)pyrrolidine-2-carboxamide
(5o)
To a mixture of L-proline (0.50 g, 4.34 mmol) in 10% K2CO3 (10 mL) and THF (10 mL)
was added 8-quinolinesulfonyl chloride (1.98 g, 8.68 mmol), and the resulting mixture was
stirred at 50 °C for 5 h. After cooling to room temperature, the reaction mixture was
acidified with 3 N aqueous HCl to pH 2 and then extracted with EtOAc (3 × 30 mL).
Separation and drying of the combined organic extracts (MgSO4), followed by removal of
solvent under reduced pressure afforded (S)-1-(quinolin-8-ylsulfonyl)pyrrolidine-2-
carboxylic acid as a white solid (0.80 g, 60% yield) that did not require further purification
and was used in the next step. To a solution of (S)-1-(quinolin-8-ylsulfonyl)pyrrolidine-2-
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carboxylic acid (0.060 g, 0.20 mmol) in DMF (0.75 mL) was added 2,5- dimethylaniline
(0.024 mL, 0.20 mmol), HATU (0.082 g, 0.22 mmol), and DIPEA (0.097 mL, 0.59 mmol).
The reaction mixture was stirred for 2 h at room temperature, then diluted with CH2Cl2 (5
mL) and washed sequentially with aqueous 10% HCl (2 × 5 mL), saturated aqueous
NaHCO3 (2 × 5 mL), and water (2 × 5 mL). The separated organic extracts were dried
(MgSO4), and evaporated to give the crude product which was purified by silica gel flash
column chromatography (2% MeOH in CH2Cl2) to afford (S)-N-(2,5-dimethylphenyl)-1-
(quinolin-8-ylsulfonyl)pyrrolidine-2-carboxamide as a colorless oil (0.050 g, 62% yield). 1H
NMR (500 MHz; CDCl3): δ (ppm) 9.54 (s, 1H), 8.88 (dd, J = 4.3 and 1.8 Hz, 1H), 8.62 (dd,
J = 7.4 and 1.4 Hz, 1H), 8.28 (dd, J = 8.4 and 1.7 Hz, 1H), 8.11 (dd, J = 8.2 and 1.3 Hz, 1H),
7.69 (t, J = 7.8 Hz, 1H), 7.63 (s, 1H), 7.53 (dd, J = 8.3 and 4.3 Hz, 1H), 7.11 (d, J = 7.7 Hz,
1H), 6.93 (d, J = 7.6 Hz, 1H), 5.41 (dd, J = 7.9 and 2.0 Hz, 1H), 3.44-3.32 (m, 2H),
2.52-2.40 (m, 1H), 2.33 (s, 6H), 1.96-1.82 (m, 2H), 1.82-1.72 (m, 1H). 13C NMR (126 MHz;
CDCl3): δ (ppm) 170.66, 151.58, 143.91, 137.12, 136.37, 135.88, 135.29, 134.92, 134.62,
130.45, 129.29, 127.65, 126.34, 125.84, 124.23, 122.51, 63.20, 49.29, 30.19, 24.98, 21.24,
17.65. LCMS purity (214 nm) =100%. HRMS: m/z calcd for C22H23N3O3S (M + H+)
410.1533, found 410.1532. Enantiomeric excess was determined by HPLC analysis: [α]D25
−31.5 (c 0.0039 CHCl3), > 99% ee.
Time of Addition Assay
HEp-2 cells were plated in 96 well black tissue culture plates at 10,000 cells per well in 100
µL and incubated 24 h at 37 °C, 5% CO2. Test compounds were diluted in media to give a
final concentration of 25 µM and added to plates in triplicate at −1, 0, 1, 2, 3, 5, 7, 21 and 24
h post-infection. Cells were infected with hRSV strain Long at an MOI of 3.0 at time point 0
and incubated for 6 days at 37 °C, 5% CO2. Following a six day incubation period, the assay
plates were equilibrated to room temperature for 30 min. An equal volume (100 µL) of Cell
Titer-Glo reagent (Promega Inc.) was added to each well using a WellMate (Matrix,
Hudson, NH) and the plates were incubated for an additional 10 min at room temperature.
At the end of the incubation, luminescence was measured using a multi-label reader
(PerkinElmer, Wellesley, MA) with an integration time of 0.1 s. Ribavirin was used as a
control compound.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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ABBREVIATIONS USED
hRSV human respiratory syncytial virus
COPD chronic obstructive pulmonary disease
GMP guanosine monophosphate
GTP guanosine triphosphate
IMPDH inosine monophosphate dehydrogenase
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MLSMR Molecular Libraries Small Molecule Repository
PBS phosphate buffered saline
PI post infection
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Structure of ribavirin 1
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Shaded regions of hit compound 2 optimized by structure-activity relationships.
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Comparison of ribavirin with analogs 5b, 5o and 5t in a time of addition assay.
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Scheme 1. Chemical Synthesis of Sulfonylpyrrolidine Analogs
Reagents and conditions: (a) L-proline, 10% aq. K2CO3, THF, 50 °C, 5 h, then 3N HCl; (b)
DIPEA, HATU, substituted aniline, DMF, rt, 2 h.
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